See more : EMS Limited (EMSLIMITED.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Tango Therapeutics, Inc. (TNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tango Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Oruka Therapeutics Inc. (ORKA) Income Statement Analysis – Financial Results
- CITIC Securities Company Limited (CIIHF) Income Statement Analysis – Financial Results
- Soma Textiles & Industries Limited (SOMATEX.BO) Income Statement Analysis – Financial Results
- Embracer Group AB (publ) (EMBRAC-B.ST) Income Statement Analysis – Financial Results
- WindowMaster International A/S (WMA.CO) Income Statement Analysis – Financial Results
Tango Therapeutics, Inc. (TNGX)
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Cost of Revenue | 115.20M | 4.03M | 1.97M | 1.63M | 32.27M |
| Gross Profit | -78.67M | 20.83M | 35.08M | 6.03M | -7.63M |
| Gross Profit Ratio | -215.38% | 83.80% | 94.69% | 78.77% | -30.93% |
| Research & Development | 115.20M | 105.91M | 77.64M | 49.99M | 32.27M |
| General & Administrative | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Other Expenses | 0.00 | 2.95M | 247.00K | 120.00K | 0.00 |
| Operating Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 7.15M |
| Cost & Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 39.43M |
| Interest Income | 6.62M | 1.46M | 495.00K | 108.00K | 684.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.42M | 4.03M | 1.97M | 1.63M | 643.00K |
| EBITDA | -111.76M | -109.46M | -57.29M | -51.48M | -14.52M |
| EBITDA Ratio | -305.96% | -446.79% | -157.09% | -672.44% | -58.90% |
| Operating Income | -114.17M | -111.07M | -58.19M | -52.20M | -15.16M |
| Operating Income Ratio | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Total Other Income/Expenses | 12.56M | 2.95M | 247.00K | 228.00K | 1.07M |
| Income Before Tax | -101.61M | -108.12M | -57.94M | -51.97M | -14.10M |
| Income Before Tax Ratio | -278.18% | -434.92% | -156.43% | -678.84% | -57.18% |
| Income Tax Expense | 134.00K | 54.00K | 292.00K | -108.00K | 0.00 |
| Net Income | -101.74M | -108.18M | -58.24M | -51.86M | -14.10M |
| Net Income Ratio | -278.54% | -435.14% | -157.21% | -677.43% | -57.18% |
| EPS | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EPS Diluted | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Weighted Avg Shares Out | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
| Weighted Avg Shares Out (Dil) | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
Why Shares of Tango Therapeutics Are Dropping Monday
What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'
Why Shares of Tango Therapeutics Climbed This Week
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
Tango Therapeutics Announces Updates to Its Board of Directors
Up 126% in 3 Days, Is Tango Therapeutics a Buy Right Now?
Why Shares of Tango Therapeutics Skyrocketed This Week
Tango Stock Surges On Peer Data Merits Excitement And Perspective
Tango Therapeutics Announces $80 million Private Placement Financing
Source: https://incomestatements.info
Category: Stock Reports